FDAnews
www.fdanews.com/articles/134167-telaprevir-gets-priority-review-begins-phase-iii-trials

Telaprevir Gets Priority Review, Begins Phase III Trials

February 10, 2011
The FDA has granted priority review to Vertex’s telaprevir, an oral protease inhibitor to treat hepatitis C (HCV), tightening its race with Merck’s boceprevir, which received priority review earlier in January. A decision on telaprevir is expected by May 23, Vertex said. Merck declined to provide the expected action date for boceprevir, though it is thought to be in May or June. Both drugs are oral, would be administered with standard of care treatment (pegylated interferon and ribavirin) and dosed three times daily, and would be indicated for patients with genotype 1 HCV.
Clinical Trials Advisor